Investigating a New Approach
In this study, we delve into the efficacy of a blended mobile-based lifestyle intervention for women with glucose intolerance following gestational diabetes mellitus (GDM). Traditional interventions postpartum have shown limited effectiveness, prompting us to explore innovative strategies to support these women in managing their health.
Background
Understanding the Risk
Women who experience glucose intolerance after GDM are at a heightened risk of developing type 2 diabetes. Despite the known risks, traditional lifestyle interventions in the early postpartum period have often fallen short in achieving long-term health outcomes for these individuals.
Methods
Design of the Study
This prospective, double-arm, non-masked, multicenter randomized controlled trial (RCT) aimed to evaluate the effectiveness of a one-year blended-care, telephone- and mobile-based lifestyle program compared to usual care. Women diagnosed with glucose intolerance 6–16 weeks after a GDM-complicated pregnancy were randomly assigned to either the intervention or control group.
Findings
Key Results
Between April 10th, 2019, and May 13th, 2022, a total of 240 participants were enrolled, with 167 completing the study. While the primary outcome of achieving weight goals did not significantly differ between the intervention and control groups, women in the intervention group demonstrated a lower incidence of metabolic syndrome. Additionally, they reported reduced sedentary behavior and increased motivation for maintaining healthy habits.
Interpretation
Uncovering Insights
Although the mobile-based lifestyle intervention did not result in significant weight loss outcomes, it proved effective in reducing the risk of developing metabolic syndrome. These findings highlight the potential of technology-enabled interventions in promoting long-term health benefits for women with glucose intolerance post-GDM.
Funding
Acknowledging Support
This research was made possible through the generous support of the Research fund of University Hospitals Leuven, Novo Nordisk, Sanofi, AstraZeneca, Boehringer-Ingelheim, and Lilly.